Publications by authors named "Pongwut Danchaivijitr"

Article Synopsis
  • - Patients with advanced/metastatic urothelial carcinoma who previously responded to or maintained stable disease with pembrolizumab immunotherapy may benefit from retreatment after disease progression, based on a post hoc analysis involving 49 patients from earlier clinical trials.
  • - The study found that 41% of these patients achieved an objective response following retreatment, with a notable percentage having had a complete response during the initial treatment, and the median duration of the response was around 14 months.
  • - Additionally, the retreatment led to manageable adverse effects, with only 45% experiencing treatment-related events, indicating that pembrolizumab retreatment is a viable and relatively safe option for select patients.
View Article and Find Full Text PDF
Article Synopsis
  • * Datopotamab deruxtecan (Dato-DXd) is a promising new treatment being tested for these patients, showing good anti-tumor effects and safety.
  • * The TROPION-Lung07 study is a Phase III trial evaluating the effectiveness of Dato-DXd combined with pembrolizumab (with or without chemotherapy) compared to the current standard treatment, focusing on progression-free and overall survival rates (NCT05555732).
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the effectiveness of amivantamab plus lazertinib compared to osimertinib in treating patients with advanced non-small-cell lung cancer (NSCLC) caused by specific genetic mutations.
  • - Results showed that patients receiving the amivantamab-lazertinib treatment had a significantly longer progression-free survival (23.7 months) than those on osimertinib (16.6 months), and the response rate was similar among both groups.
  • - Side effects primarily related to treatment were noted, but the overall survival analysis indicated a potential benefit for amivantamab-lazertinib over osimertinib, with fewer serious complications leading to treatment discontinuation.
View Article and Find Full Text PDF
Article Synopsis
  • A Phase III study tested the efficacy of subcutaneous versus intravenous amivantamab for patients with advanced non-small cell lung cancer (NSCLC) who had progression after prior treatments.
  • Results showed that the subcutaneous form maintained efficacy, with fewer side effects and a significantly longer overall survival, while also being more convenient to administer.
  • Patients receiving subcutaneous amivantamab had less infusion-related reactions and faster administration times, with 85% finding the treatment convenient compared to only 35% in the intravenous group.
View Article and Find Full Text PDF

Background: Comprehensive molecular profiling of tissue samples that can help guide therapy management is not widely available across the globe.

Methods: Comprehensive molecular profiling through Caris Molecular Intelligence involves the analysis of DNA through next-generation sequencing, chromogenic or fluorescent in situ hybridization, pyrosequencing, and copy number alterations; RNA through whole-transcriptome sequencing and multiplex PCR of RNA; and protein through immunohistochemistry.

Results: Here we describe the experience of molecular profiling of tumor tissue samples from patients diagnosed with advanced solid tumors and treated in two countries, the United Arab Emirates and Thailand.

View Article and Find Full Text PDF

Purpose: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CRT-AC) and induction chemotherapy followed by concurrent chemoradiotherapy (IC-CRT) are among the best treatments in nasopharyngeal carcinoma (NPC). This study aimed to develop a model for deciding the sequence of chemotherapy in NPC.

Methods: Data were separated into two cohorts.

View Article and Find Full Text PDF
Article Synopsis
  • Lazertinib, a targeted therapy for EGFR-mutated lung cancer, demonstrated better progression-free survival compared to gefitinib in patients with central nervous system (CNS) metastases in the LASER301 study.
  • The study included treatment-naive patients with advanced NSCLC who were randomized to receive either lazertinib or gefitinib, with regular CNS imaging to assess treatment effects.
  • Results showed that patients treated with lazertinib had a median intracranial progression-free survival of 28.2 months, significantly longer than the 8.4 months for those treated with gefitinib, indicating lazertinib's effectiveness in managing CNS metastases.
View Article and Find Full Text PDF
Article Synopsis
  • Lazertinib is a new targeted therapy for non-small cell lung cancer (NSCLC) that has shown better efficacy than gefitinib in a study focused on Asian patients with specific EGFR mutations.
  • The LASER301 phase 3 study found that patients receiving lazertinib had a significantly longer progression-free survival (20.6 months) compared to those on gefitinib (9.7 months).
  • Both medications had similar safety profiles, with only slight differences in adverse events leading to discontinuation, making lazertinib a promising option for treating these patients.
View Article and Find Full Text PDF
Article Synopsis
  • Lazertinib, a third-generation EGFR tyrosine kinase inhibitor, was tested in a global phase III study (LASER301) against gefitinib for treating patients with advanced non-small-cell lung cancer (NSCLC) who had specific EGFR mutations.
  • The study included 393 treatment-naïve patients and found that those taking lazertinib had a significantly longer median progression-free survival (20.6 months) compared to gefitinib (9.7 months), with similar overall response rates for both treatments.
  • Ultimately, lazertinib showed improved efficacy over gefitinib in managing advanced NSCLC, while maintaining a safety profile consistent with previous findings.
View Article and Find Full Text PDF

Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung cancer who were selected for biomarker status using blood-based targeted next-generation sequencing. In the Phase 3 cohort C evaluating blood-based (b)TMB as a biomarker of atezolizumab efficacy, patients with bTMB of ≥10 (N = 471) were randomized 1:1 to receive atezolizumab or platinum-based chemotherapy per local standard of care.

View Article and Find Full Text PDF

Background: Though concurrent chemoradiotherapy (CCRT) with cisplatin remains a standard of care for patients with locally advanced nasopharyngeal carcinoma (LA-NPC), carboplatin has alternatively been used without sufficient supportive evidences. Thus, we evaluated an efficacy and tolerability of carboplatin CCRT compared with cisplatin in LA-NPC patients.

Methods: Patients with LA-NPC treated with CCRT were identified through the Thai multicenter head and neck cancer database.

View Article and Find Full Text PDF

Purpose: Prophylactic percutaneous endoscopic gastrostomy (PPEG) is widely used for patients with head and neck cancer undergoing concurrent chemoradiation (CCRT). Nevertheless, the necessity of its use in patients with nasopharyngeal cancer (NPC) is uncertain. This study aimed to evaluate the benefits of PPEG on prevention of weight loss and treatment tolerance in patients with NPC receiving CCRT.

View Article and Find Full Text PDF

Background: Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking.

Methods: PARACHUTE is a phase IV, prospective, non-interventional, observational study. Primary endpoint was the proportion of patients remaining progression free at 12 months.

View Article and Find Full Text PDF

Introduction: The mainstay systemic treatment for non-oncogenic addictive advanced stage non-small cell lung cancer is chemotherapy. Anti-angiogenic agents are additive compounds that enhance disease control and lead to improvement of overall survival benefit. Recently PD-(L)1 blockage, a checkpoint inhibitor, has been adopted as another line of treatment.

View Article and Find Full Text PDF

Background: Chemoradiotherapy (CRT) with high cumulative doses (CDs) of cisplatin has been considered the standard of care for non-metastatic nasopharyngeal carcinoma (NPC). However, given most patients' inability to tolerate high CDs due to cisplatin-related toxicities, the optimal CD of cisplatin during CRT remains undetermined.

Methods: Patients with non-metastatic NPC who received CRT with cisplatin between 2007 and 2017 were identified through the Thai head and neck cancer multicenter database and then categorized according to cisplatin CD (mg/m) received.

View Article and Find Full Text PDF

Purpose: We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC).

Methods: Patients who received doxorubicin + cyclophosphamide or cisplatin were given intravenous ondansetron and dexamethasone prior to chemotherapy and oral dexamethasone on days 2-4 and randomized 1:1:1 to receive APR125 on day 1 and APR80 on days 2-3 or OLN10 or OLN5 on days 1-4. Matched placebo controls were used.

View Article and Find Full Text PDF

Background: Based on the tumor-driven concomitant activation of angiogenesis and coagulation we conducted a phase I combination study of sunitinib with the low molecular weight heparin dalteparin in patients with metastatic clear cell renal cell carcinoma (ccRCC).

Materials And Methods: Patients received standard treatment with sunitinib (50 mg daily, 4 weeks on, 2 weeks off). During the second week of no sunitinib in the first cycle (week 6) patients received dalteparin monotherapy (in escalating doses).

View Article and Find Full Text PDF

Background: We sought to identify potential clinical variables associated with outcomes after radium-223 therapy in routine practice.

Methods: Consecutive non-trial mCRPC patients who received ≥1 dose of radium dichloride-223 at four academic and one community urology-specific cancer centers from May 2013 to June 2014 were retrospectively identified. Association of baseline and on-therapy clinical variables with number of radium doses received and clinical outcomes including overall survival were analyzed using chi-square statistics, cox proportional hazards, and Kaplan-Meier methods.

View Article and Find Full Text PDF

Purpose: The purpose of this study is to determine the efficacy of ginger for reducing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving adriamycin and cyclophosphamide (AC) regimens.

Methods: We enrolled breast cancer patients receiving AC who experienced moderate to severe nausea or vomiting during the first chemotherapy cycle. Subjects were randomized to receive a 500-mg ginger capsule or placebo twice a day for 5 days starting on the first day of the second AC cycle and were switched to the other treatment in the third cycle.

View Article and Find Full Text PDF